Altimmune ALT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$88.09M+7.3% | -$95.06M-7.5% | -$88.45M-4.4% | -$84.71M+12.7% | ||
| $112K-52.9% | $238K-50.1% | $477K+333% | -$205K-137% | ||
| $16.08M+11.7% | $14.39M+35.3% | $10.64M+31.3% | $8.1M+46.8% | ||
| -$67.54M+15.4% | -$79.85M-5.3% | -$75.81M-21.1% | -$62.59M+20.0% | ||
| —— | —— | —— | $126K-99.0% | ||
| -$132.47M— | —— | —— | -$74.38M-185% | ||
| $206.84M+1,959% | $10.04M-88.3% | $86.11M+51.5% | $56.82M-12.7% | ||
| —— | -$103.64M-531% | $24.03M+130% | -$79.2M-206% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Altimmune generate?
- Altimmune (ALT) generated -$71.6M in operating cash flow over the trailing twelve months.
- What is Altimmune's free cash flow?
- After $111.0K of capital expenditures, Altimmune's free cash flow was -$68.8M over the trailing twelve months, up 10.2% year over year.
- Where does Altimmune's cash flow data come from?
- Every line is extracted from Altimmune's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
